08.06.2016 • NewsDede WillamsshkreliRetrophin

Shkreli Pleads “Not Guilty” to Conspiracy

Martin Shkreli, the 33-year-old former CEO of Turing Pharmaceuticals, has pleaded “not guilty” to a conspiracy charge accusing him of using employees and consultants to conceal his control of Retrophin, a company he founded and once headed. Shkreli and Turing made headlines when the company jacked up the price of Daraprim (pyrimethamine), a 62-year-old drug used to treat the deadly parasitic infection toxoplasmosis, from $13.50 to $700 a tablet, shortly after acquiring marketing rights in August of last year.

Turing’s former lawyer, Evan Greebel, who is accused of aiding Shkreli, also pleaded not guilty to the charge in the ongoing securities fraud case. Arrested in December 2015, Shrekli was accused of siphoning off $11 million in assets from Retrophin – which later fired him – to pay off defrauded investors from his failed hedge fund, MSMB Capital Management.

At the time, federal prosecutor Robert Capers said Shkreli ran Retrophin and the hedge funds like a Ponzi scheme and a “personal piggy bank.” In a new indictment filed last week, the former manager is also accused of secretly hiding his control of unrestricted stock in the company, which prosecutors say he also used to pay down debt.

The Daraprim case set off a national furor over drug pricing in the US.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.